Bioneer Corporation (064550) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioneer Corporation (064550) has a cash flow conversion efficiency ratio of 0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩860.54 Million ≈ $583.18K USD) by net assets (₩229.21 Billion ≈ $155.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Bioneer Corporation leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
Bioneer Corporation - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Bioneer Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Bioneer Corporation market cap and net worth for the company's overall valuation and market capitalisation.
Bioneer Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioneer Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WiSoL CO.LTD
KQ:122990
|
0.024x |
|
Mobile Infrastructure Corporation
NYSE MKT:BEEP
|
0.007x |
|
Harrisons Holdings (Malaysia)
KLSE:5008
|
0.095x |
|
Sastasundar Ventures Limited
NSE:SASTASUNDR
|
-0.031x |
|
Wealth First Portfolio Managers Limited
NSE:WEALTH
|
0.069x |
|
Schloss Wachenheim AG
F:SWA
|
-0.008x |
|
Yirendai Ltd
NYSE:YRD
|
-0.001x |
|
Pha Lai Thermal Power JSC
VN:PPC
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Bioneer Corporation (2014–2024)
The table below shows the annual cash flow conversion efficiency of Bioneer Corporation from 2014 to 2024. View 064550 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩226.89 Billion ≈ $153.76 Million |
₩-13.48 Billion ≈ $-9.13 Million |
-0.059x | -437.31% |
| 2023-12-31 | ₩234.88 Billion ≈ $159.17 Million |
₩4.14 Billion ≈ $2.80 Million |
0.018x | -52.80% |
| 2022-12-31 | ₩236.00 Billion ≈ $159.94 Million |
₩8.81 Billion ≈ $5.97 Million |
0.037x | -85.75% |
| 2021-12-31 | ₩203.05 Billion ≈ $137.60 Million |
₩53.17 Billion ≈ $36.04 Million |
0.262x | -60.16% |
| 2020-12-31 | ₩145.61 Billion ≈ $98.68 Million |
₩95.71 Billion ≈ $64.86 Million |
0.657x | +459.95% |
| 2019-12-31 | ₩30.61 Billion ≈ $20.74 Million |
₩-5.59 Billion ≈ $-3.79 Million |
-0.183x | +12.25% |
| 2018-12-31 | ₩38.99 Billion ≈ $26.42 Million |
₩-8.11 Billion ≈ $-5.50 Million |
-0.208x | -44.77% |
| 2017-12-31 | ₩27.15 Billion ≈ $18.40 Million |
₩-3.90 Billion ≈ $-2.64 Million |
-0.144x | +8.26% |
| 2016-12-31 | ₩26.11 Billion ≈ $17.70 Million |
₩-4.09 Billion ≈ $-2.77 Million |
-0.157x | -1427.23% |
| 2015-12-31 | ₩34.53 Billion ≈ $23.40 Million |
₩407.68 Million ≈ $276.28K |
0.012x | +108.26% |
| 2014-12-31 | ₩30.20 Billion ≈ $20.47 Million |
₩-4.31 Billion ≈ $-2.92 Million |
-0.143x | -- |
About Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more